In summary, our preclinical findings propose the therapeutic co-targeting of CXCR4 and β2AR pathways and support the addition of propranolol to GPC-100 for HSC mobilization for ASCT in MM patients. This evidence concerns the gene CXCR4 and Miyoshi myopathy.